“Our commitment to advancing our late-stage programs was reflected in the progress we made in the first quarter of the year. Both EPKINLY and Tivdak expanded their reach with approvals in additional territories and the updated Rina-S data presented at SGO reinforces its potential as a treatment option for patients with advanced ovarian cancer,” said Jan van de Winkel, CEO.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab Executes Share Buy-back Transactions in Early May 2025
- Genmab to Submit sBLA for Epcoritamab Combination in Follicular Lymphoma
- Genmab Continues Share Buy-back Program in April 2025
- Genmab price target lowered to DKK 1,990 from DKK 2,970 at HSBC
- Genmab’s Strong Market Position and Growth Potential Justifies Buy Rating